P55PIK Regulates P53-Dependent Apoptosis in Cancer Cells by Interacting with P53 DNA-Specific Domain

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Jul 2

PMID 32606738

Authors

Chaoxing Li

Wenwen Li

Xiyao Cheng

Dapeng Zhang

Xiang Sun

Jingjing Zhou

Yin Zhou

Yongqi Huang

Xianmin Xia

Qi Ma

Zhengding Su

Affiliations

Soon will be listed here.

Abstract

Purpose: Phosphatidylinositol 3-kinase (PI3K) plays an important role in tumorigenesis by cross-talking with several signaling pathways. p55PIK is a unique regulatory subunit of PI3K and contains an extra 24-residue N-terminal domain (N24). This study aimed to explore the interaction of p55PIK with p53 and the role of p55PIK in regulating p53-dependent apoptosis in cancer cells.

Materials And Methods: The expression of p55PIK was detected in cancer cells, and the interaction of p55PIK with p53 was examined by immunoprecipitation and pull-down assay. The expression of p53-dependent apoptosis-related genes was detected by PCR.

Results: N24 domain of p55PIK interacted with DNA-specific binding domain (DBD) of p53. The increase or decrease of p55PIK expression led to the change of the expression of p53 and p53-regulated genes in cancer cells. Moreover, N24 peptide led to the change of the expression of p53-regulated genes. Moreover, a membrane-permeable N24 peptide enhanced p53-dependent apoptosis induced by methyl methanesulfonate.

Conclusion: Our results reveal a novel mechanism that regulates p53-dependent apoptosis in cancer cells via p55PIK-p53 interaction.

References

Hu J, Xia X, Cheng A, Wang G, Luo X, Reed M . A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy. Mol Cancer Ther. 2008; 7(12):3719-28. DOI: 10.1158/1535-7163.MCT-08-0499. View

Lai S, Wang G, Cao X, Luo X, Wang G, Xia X . KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors. Oncotarget. 2015; 7(2):1367-79. PMC: 4811466. DOI: 10.18632/oncotarget.6011. View

Ye G, Sun G, Cheng Z, Zhang L, Hu K, Xia X . p55PIK regulates alpha-fetoprotein expression through the NF-κB signaling pathway. Life Sci. 2017; 191:104-110. DOI: 10.1016/j.lfs.2017.09.043. View

Lv F, You W, Yu Y, Hu J, Zhang B, Wang J . Effects of the 24 N-terminal amino acids of p55PIK on endotoxinstimulated release of inflammatory cytokines by HaCaT cells. J Huazhong Univ Sci Technolog Med Sci. 2013; 33(4):587-593. DOI: 10.1007/s11596-013-1163-2. View

Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B . The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010; 11(5):329-41. DOI: 10.1038/nrm2882. View

Cully M, You H, Levine A, Mak T . Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006; 6(3):184-92. DOI: 10.1038/nrc1819. View

Sun X, Zhao M, Yuan X, Yu Q, Zheng L, Fang M . [Inhibitory effect of N-terminal of p55PIK--regulatory subunit of phosphoinositide-3 kinase--on proliferation of gastric cancer cell line MGC803 and its mechanism]. Ai Zheng. 2006; 25(3):264-8. View

Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield M . Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001; 17:615-75. DOI: 10.1146/annurev.cellbio.17.1.615. View

Deng Y, Wang J, Wang G, Jin Y, Luo X, Xia X . p55PIK transcriptionally activated by MZF1 promotes colorectal cancer cell proliferation. Biomed Res Int. 2013; 2013:868131. PMC: 3591147. DOI: 10.1155/2013/868131. View

10.

Xia X, Serrero G . Multiple forms of p55PIK, a regulatory subunit of phosphoinositide 3-kinase, are generated by alternative initiation of translation. Biochem J. 1999; 341 ( Pt 3):831-7. PMC: 1220424. View

11.

Wang J, Liao A, Thakur K, Zhang J, Huang J, Wei Z . Licochalcone B Extracted from Glycyrrhiza uralensis Fisch Induces Apoptotic Effects in Human Hepatoma Cell HepG2. J Agric Food Chem. 2019; 67(12):3341-3353. DOI: 10.1021/acs.jafc.9b00324. View

12.

Thorpe L, Yuzugullu H, Zhao J . PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2014; 15(1):7-24. PMC: 4384662. DOI: 10.1038/nrc3860. View

13.

Inukai K, Anai M, van Breda E, Hosaka T, Katagiri H, Funaki M . A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene. J Biol Chem. 1996; 271(10):5317-20. DOI: 10.1074/jbc.271.10.5317. View

14.

Wang G, Cao X, Lai S, Luo X, Feng Y, Wu J . Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer. Oncogene. 2014; 34(7):912-21. DOI: 10.1038/onc.2014.30. View

15.

Wang G, Deng Y, Cao X, Lai S, Tong Y, Luo X . Blocking p55PIK signaling inhibits proliferation and induces differentiation of leukemia cells. Cell Death Differ. 2012; 19(11):1870-9. PMC: 3469064. DOI: 10.1038/cdd.2012.70. View

16.

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

17.

Wang G, Cao X, Lai S, Luo X, Feng Y, Xia X . PI3K stimulates DNA synthesis and cell-cycle progression via its p55PIK regulatory subunit interaction with PCNA. Mol Cancer Ther. 2013; 12(10):2100-9. DOI: 10.1158/1535-7163.MCT-12-0920. View

18.

Ma M, Wang X, Chen X, Cai R, Chen F, Dong W . MicroRNA-432 targeting E2F3 and P55PIK inhibits myogenesis through PI3K/AKT/mTOR signaling pathway. RNA Biol. 2017; 14(3):347-360. PMC: 5367255. DOI: 10.1080/15476286.2017.1279786. View

19.

Sun Y, Thakur K, Hu F, Zhang J, Wei Z . Icariside II inhibits tumorigenesis via inhibiting AKT/Cyclin E/ CDK 2 pathway and activating mitochondria-dependent pathway. Pharmacol Res. 2019; 152:104616. DOI: 10.1016/j.phrs.2019.104616. View

20.

Latonen L, Kurki S, Pitkanen K, Laiho M . p53 and MDM2 are regulated by PI-3-kinases on multiple levels under stress induced by UV radiation and proteasome dysfunction. Cell Signal. 2002; 15(1):95-102. DOI: 10.1016/s0898-6568(02)00044-x. View